Clinical experience with fenticonazole 2% formulation in the treatment of dermatomycoses and pityriasis versicolor.
Clinical efficacy of fenticonazole 2% cream has been tested on 30 patients with dermatomycoses and the 2% nebulized lotion on 10 patients with pityriasis versicolor. Treatment consisted of two topical applications of the drug for up to 5 weeks and clinical improvement and mycology were assessed at one-week intervals. Thirty-six patients (90%) were cured at the end of the 5-week period; 26 were cured from dermatomycoses and 10 from pityriasis versicolor. No recurrency/reinfection nor side-effects were encountered. The success attained by fenticonazole treatment indicates that it is a first choice drug in the therapy of superficial dermatomycoses.
University Dermatological Clinic, Cagliari, Italy.
N
N
Aste
M
M
Pau
M
M
Zucca
P
P
Biggio
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D003881:Dermatomycoses / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D009824:Ointments; D014010:Tinea Versicolor / Q000188:drug therapy*
D007093:Imidazoles; D009824:Ointments; C033486:fenticonazole